Ascent Group LLC Trims Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ascent Group LLC has reduced its stake in Thermo Fisher Scientific Inc. by 11.4%, bringing its total shares to 7,844, valued at approximately $3.18 million.
• Insider transactions have occurred, with CAO Joseph R. Holmes and CEO Marc N. Casper selling 385 and 400 shares respectively, reflecting a decrease in their ownership.
• Thermo Fisher reported strong earnings of $5.36 per share for its most recent quarter, exceeding expectations, along with a revenue of $10.86 billion, up 2.9% year-over-year.

Ascent Group LLC reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,844 shares of the medical research company's stock after selling 1,007 shares during the quarter. Ascent Group LLC's holdings in Thermo Fisher Scientific were worth $3,180,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Barrett & Company Inc. increased its holdings in Thermo Fisher Scientific by 377.4% during the 2nd quarter. Barrett & Company Inc. now owns 253 shares of the medical research company's stock worth $103,000 after purchasing an additional 200 shares during the period. Two Point Capital Management Inc. bought a new position in Thermo Fisher Scientific in the second quarter worth approximately $4,143,000. Ameritas Advisory Services LLC raised its stake in Thermo Fisher Scientific by 5.1% in the second quarter. Ameritas Advisory Services LLC now owns 3,991 shares of the medical research company's stock worth $1,618,000 after buying an additional 195 shares in the last quarter. HighMark Wealth Management LLC raised its stake in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after buying an additional 45 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new position in Thermo Fisher Scientific in the second quarter worth approximately $1,425,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the company's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $543.88 on Friday. The firm has a market capitalization of $205.37 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company's fifty day moving average price is $482.58 and its 200-day moving average price is $447.27.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's payout ratio is 9.95%.

Analyst Ratings Changes

TMO has been the subject of a number of recent research reports. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, HSBC reaffirmed a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.